Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 335 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

335 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 335 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

335 programs

Clinical programs

Page 7 of 7

  1. TAK228

    Takeda

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  2. TD-8954

    Takeda

    Enteral Feeding Intolerance

    phase 2 small molecule completed

    1 trial

  3. TDV

    Takeda

    Healthy

    phase 2 mab completed

    1 trial

  4. TDV Liquid Formulation 1

    Takeda

    Dengue Fever

    phase 2 small molecule completed

    1 trial

  5. TIMP-GLIA

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    2 trials

  6. Tak-228 & Tak-117

    Takeda

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  7. Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

    Takeda

    Dengue Fever

    phase 2 mab completed

    2 trials

  8. Teduglutide

    Takeda

    Postoperative Fistula

    phase 2 small molecule completed

    1 trial

  9. Teduglutide (ALX-0600)

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  10. Tislelizumab

    Takeda

    Minimal Residual Disease

    phase 2 small molecule active

    1 trial

  11. Udenafil

    Takeda

    Erectile Dysfunction

    phase 2 small molecule terminated

    2 trials

  12. VP20621

    Takeda

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  13. Vedolizumab

    Takeda

    Collagenous Gastritis

    phase 2 mab active

    1 trial

  14. Vedolizumab

    Takeda

    Celiac Disease

    phase 2 small molecule terminated

    1 trial

  15. Vedolizumab

    Takeda

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 2 small molecule completed

    2 trials

  16. Vedolizumab 300 MG Injection [Entyvio]

    Takeda

    Immune Checkpoint Inhibitor-Related Colitis

    phase 2 small molecule active

    1 trial

  17. Vedolizumab intravenous injection

    Takeda

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  18. Veltuzumab

    Takeda

    Rheumatoid Arthritis

    phase 2 small molecule terminated

    1 trial

  19. Vonoprazan

    Takeda

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial

  20. Vortioxetine

    Takeda

    Binge Eating Disorder

    phase 2 small molecule completed

    1 trial

  21. Vortioxetine (IV)

    Takeda

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  22. ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis & Moderate to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  23. ZASOCITINIB, Matching Placebo for TAK-279

    Takeda

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  24. ZED1227 + SIGE

    Takeda

    Celiac Disease

    phase 2 small molecule active

    1 trial

  25. Zasocitinib

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    2 trials

  26. Zasocitinib

    Takeda

    Nonsegmental Vitiligo

    phase 2 small molecule active

    1 trial

  27. Zasocitinib (Dose A)

    Takeda

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  28. alisertib

    Takeda

    Malignant Rhabdoid Tumor

    phase 2 small molecule active

    1 trial

  29. anagrelide hydrochloride

    Takeda

    Essential Thrombocythaemia

    phase 2 small molecule completed

    1 trial

  30. budesonide

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 2 small molecule completed

    1 trial

  31. ecallantide 60 mg

    Takeda

    ACE Inhibitor Induced Angioedema

    phase 2 small molecule terminated

    1 trial

  32. elritercept

    Takeda

    Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).

    phase 2 small molecule active

    1 trial

  33. fruquintinib

    Takeda

    Colon Cancer

    phase 2 small molecule active

    1 trial

  34. lanadelumab

    Takeda

    COVID-19

    phase 2 mab completed

    1 trial

  35. lisdexamfetamine dimesylate (SPD489)

    Takeda

    Binge Eating Disorder

    phase 2 small molecule completed

    1 trial

  36. metformin

    Takeda

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  37. peginesatide

    Takeda

    Anemia

    phase 2 small molecule completed

    5 trials

  38. pioglitazone

    Takeda

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  39. pioglitazone

    Takeda

    Asthma

    phase 2 small molecule completed

    1 trial

  40. ponatinib - Phase 1

    Takeda

    Chronic Myeloid Leukemia (CML)

    phase 2 small molecule completed

    1 trial

  41. rhHNS-10 mg

    Takeda

    Sanfilippo Syndrome

    phase 2 mab terminated

    1 trial

  42. rhIGF-1/rhIGFBP-3

    Takeda

    Retinopathy of Prematurity (ROP)

    phase 2 small molecule completed

    1 trial

  43. rhIGF-I/rhIGFBP-3

    Takeda

    Retinopathy of Prematurity (ROP)

    phase 2 small molecule completed

    1 trial

  44. troxacitabine

    Takeda

    Leukemia

    phase 2 small molecule completed

    1 trial

  45. velaglucerase alfa

    Takeda

    Gaucher Disease, Type 3

    phase 2 mab completed

    1 trial

  46. vortioxetine (Lu AA21004)

    Takeda

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  47. ΕΑΕ-2018/ΜΜ03

    Takeda

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

335 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.